FGFR2 and cholangiocarcinoma: In conjunction with FGFR2 fusions, Isocitrate dehydrogenase 1 (IDH1) mutations, the BRAF p.V600E hotspot, and others are found in approximately 30–40% of patients with cholangiocarcinoma, particularly intrahepatic subtypes [187].